Currently, Ozempic remains atop the other GLP-1 drugs on this list, but the drug has been available for longer. As the other drugs on this list become more prominent in the healthcare industry ...

A large swath of insured Americans could be eligible for a popular class of weight loss and diabetes drugs. Meanwhile, Apple ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

This analysis finds that 57.4 million adults under the age of 65 could potentially be eligible for GLP-1 drugs based on ...

The demand for medications like Ozempic continues to cause shortages for both those seeking weight loss and patients with ...

Karla Robinson, MD and Medical Editor at GoodRx discusses how GLP-1 receptor agonists work and their benefits.

GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...

It's possible that Alzheimer's disease could be added to the lengthening list of ... injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able ...

While drugmakers Novo Nordisk and Eli Lilly assert that shortages of popular weight loss and diabetes medications Wegovy, Ozempic, Mounjaro and Zepbound are easing, many patients continue to face ...

Starting price of $149 offers improved accessibility compared to market prices of brand-name medications which can be 8x ...

The popularity of the newest weight loss medications has employers reevaluating their health plans. There are a lot of unknowns, but here’s what we do know based on the data.

The anti-obesity drug market could one day be worth $100 billion. It's a massive opportunity in healthcare, and two companies that are leaders in that space today are Eli Lilly (NYSE: LLY) and ...